BR112015017242B1 - Uso de um anticorpo anti-flt-1 - Google Patents
Uso de um anticorpo anti-flt-1 Download PDFInfo
- Publication number
- BR112015017242B1 BR112015017242B1 BR112015017242-3A BR112015017242A BR112015017242B1 BR 112015017242 B1 BR112015017242 B1 BR 112015017242B1 BR 112015017242 A BR112015017242 A BR 112015017242A BR 112015017242 B1 BR112015017242 B1 BR 112015017242B1
- Authority
- BR
- Brazil
- Prior art keywords
- flt
- antibody
- muscle
- antigen
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361757571P | 2013-01-28 | 2013-01-28 | |
| US61/757,571 | 2013-01-28 | ||
| PCT/US2014/013402 WO2014117160A1 (en) | 2013-01-28 | 2014-01-28 | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015017242A2 BR112015017242A2 (https=) | 2017-08-15 |
| BR112015017242B1 true BR112015017242B1 (pt) | 2023-11-07 |
Family
ID=50073518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015017242-3A BR112015017242B1 (pt) | 2013-01-28 | 2014-01-28 | Uso de um anticorpo anti-flt-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9957324B2 (https=) |
| EP (1) | EP2948476B1 (https=) |
| JP (2) | JP6469022B2 (https=) |
| KR (1) | KR102259255B1 (https=) |
| CN (1) | CN104955843B (https=) |
| AU (1) | AU2014209012B2 (https=) |
| BR (1) | BR112015017242B1 (https=) |
| CA (1) | CA2898998C (https=) |
| EA (1) | EA037501B1 (https=) |
| ES (1) | ES2676406T3 (https=) |
| HK (1) | HK1213918A1 (https=) |
| IL (1) | IL238588B (https=) |
| MX (1) | MX360153B (https=) |
| WO (1) | WO2014117160A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10729746B2 (en) | 2013-01-28 | 2020-08-04 | Shire Human Genetic Therapies, Inc. | Recombinant placenta growth factor for treating Duchenne muscular dystrophy |
| CN107683143A (zh) * | 2015-04-07 | 2018-02-09 | 夏尔人类遗传性治疗公司 | 治疗支气管肺发育不良的抗flt‑1抗体 |
| MA41899A (fr) * | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| CN107690335A (zh) | 2015-04-07 | 2018-02-13 | 夏尔人类遗传性治疗公司 | 治疗支气管肺发育不良的抗flt‑1抗体 |
| KR102019048B1 (ko) | 2017-02-06 | 2019-09-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법 |
| KR101886788B1 (ko) | 2017-02-07 | 2018-08-09 | 가톨릭대학교 산학협력단 | MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법 |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| KR20230140362A (ko) | 2022-03-24 | 2023-10-06 | 주식회사 케이에스비튜젠 | 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7972596B2 (en) * | 2004-11-18 | 2011-07-05 | Imclone Llc | Antibodies against vascular endothelial growth factor receptor-1 |
-
2014
- 2014-01-28 KR KR1020157021136A patent/KR102259255B1/ko active Active
- 2014-01-28 CA CA2898998A patent/CA2898998C/en active Active
- 2014-01-28 ES ES14704040.6T patent/ES2676406T3/es active Active
- 2014-01-28 WO PCT/US2014/013402 patent/WO2014117160A1/en not_active Ceased
- 2014-01-28 JP JP2015555412A patent/JP6469022B2/ja active Active
- 2014-01-28 US US14/763,881 patent/US9957324B2/en active Active
- 2014-01-28 BR BR112015017242-3A patent/BR112015017242B1/pt active IP Right Grant
- 2014-01-28 EP EP14704040.6A patent/EP2948476B1/en active Active
- 2014-01-28 HK HK16101850.9A patent/HK1213918A1/zh unknown
- 2014-01-28 AU AU2014209012A patent/AU2014209012B2/en active Active
- 2014-01-28 EA EA201590720A patent/EA037501B1/ru unknown
- 2014-01-28 CN CN201480003714.6A patent/CN104955843B/zh active Active
- 2014-01-28 MX MX2015009690A patent/MX360153B/es active IP Right Grant
-
2015
- 2015-05-03 IL IL238588A patent/IL238588B/en active IP Right Grant
-
2018
- 2018-04-12 US US15/951,937 patent/US20180312593A1/en not_active Abandoned
- 2018-11-01 JP JP2018206297A patent/JP2019023230A/ja active Pending
-
2020
- 2020-07-14 US US16/928,819 patent/US20210163603A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180312593A1 (en) | 2018-11-01 |
| MX360153B (es) | 2018-10-24 |
| EA201590720A8 (ru) | 2018-09-28 |
| HK1217710A1 (en) | 2017-01-20 |
| US20150361174A1 (en) | 2015-12-17 |
| IL238588A0 (en) | 2015-06-30 |
| IL238588B (en) | 2020-04-30 |
| CN104955843A (zh) | 2015-09-30 |
| CN104955843B (zh) | 2019-08-13 |
| WO2014117160A1 (en) | 2014-07-31 |
| US20210163603A1 (en) | 2021-06-03 |
| AU2014209012A1 (en) | 2015-05-21 |
| JP2019023230A (ja) | 2019-02-14 |
| HK1213918A1 (zh) | 2016-07-15 |
| CA2898998C (en) | 2023-02-14 |
| EP2948476B1 (en) | 2018-06-06 |
| KR102259255B1 (ko) | 2021-05-31 |
| EA037501B1 (ru) | 2021-04-05 |
| EP2948476A1 (en) | 2015-12-02 |
| CA2898998A1 (en) | 2014-07-31 |
| US9957324B2 (en) | 2018-05-01 |
| JP2016511234A (ja) | 2016-04-14 |
| EA201590720A1 (ru) | 2015-11-30 |
| KR20150109386A (ko) | 2015-10-01 |
| JP6469022B2 (ja) | 2019-02-13 |
| BR112015017242A2 (https=) | 2017-08-15 |
| MX2015009690A (es) | 2016-03-31 |
| ES2676406T3 (es) | 2018-07-19 |
| AU2014209012B2 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210163603A1 (en) | Anti-flt-1 antibodies in treating duchenne muscular dystrophy | |
| JP6475639B2 (ja) | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン | |
| JP7456989B2 (ja) | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 | |
| JP2020519291A (ja) | 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用 | |
| JP2019509735A (ja) | デュシェンヌ型筋ジストロフィー治療における組換えフォリスタチン−Ｆｃ融合タンパク質及び使用 | |
| US10729746B2 (en) | Recombinant placenta growth factor for treating Duchenne muscular dystrophy | |
| HK1217710B (en) | Anti-flt-1 antibodies in treating duchenne muscular dystrophy | |
| Muñoz-Beamud et al. | 2021 peripheral nerve society virtual event | |
| BR122024023570A2 (pt) | Polinucleotídeo que codifica um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno, composição farmacêutica, usos relacionados, vetor de expressão, célula isolada e anticorpos anti-flt-1 ou seu fragmento de ligação ao antígeno | |
| BR112017021414B1 (pt) | Anticorpos anti-flt-1 e composição farmacêutica compreendendo os referidos anticorpos | |
| Kao et al. | 302 LATERALLY WEDGED SHOE INSERTS AS AN INTERVENTION FOR MEDIAL KNEE OSTEOARTHRITIS. | |
| HK1213804B (zh) | 治疗杜兴氏肌营养不良的卵泡抑素 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: REGENTS OF THE UNIVERSITY OF MINNESOTA (US) ; TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2014, OBSERVADAS AS CONDICOES LEGAIS |